Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

This study found that the binding and release of BMP-2 from kerateine biomaterials are significantly influenced by pH and salt concentration, highlighting the potential for developing improved bone repair systems.

The abstract provides a brief mention of alopecia areata (AA) being a chronic immune-mediated disorder causing non-scarring hair loss, but specific study results or findings relating to this are not reported.

This study observed that dupilumab led to significant hair regrowth and was well-tolerated in children with both alopecia areata and atopic dermatitis, showing promise as a safe treatment option for pediatric patients with associated atopy.

This study conducted a meta-analysis and found that among therapies for alopecia areata, baricitinib_4 mg was most likely to be effective, followed by ritlecitinib and ivarmacitinib, while other treatments like dupilumab and secukinumab were less effective.

In this study, 40.9% of patients taking 4 mg baricitinib and 21.2% taking 2 mg achieved significant hair regrowth over 52 weeks, indicating potential long-term benefits for adults with severe alopecia areata without introducing new safety concerns.

This study reported that some pediatric patients with alopecia areata experienced hair regrowth with dupilumab treatment, particularly those with concomitant atopic dermatitis, suggesting dupilumab may be beneficial when traditional therapies fail.

This study found that patients with alopecia areata have lower levels of RBC folate, correlating negatively with the disease's severity and extent.

In this randomized double-blind study, 160 adults with alopecia areata showed significant improvements in hair loss severity after using a bioactive peptide cosmetic product that mimics platelet-rich plasma, while the placebo group showed no significant change, underlining the treatment's potential effectiveness.

This study suggests that off-label use of baricitinib in children under 12 with alopecia areata may improve hair regrowth, but further research is needed to confirm efficacy and safety.

The article in Dermatologic Therapy discusses clinical experiences with using tofacitinib to treat alopecia areata in 63 patients, but no specific results are reported in the abstract.

This study found that the L457(3.43)R mutation in the human luteinizing hormone receptor increases phosphodiesterase activity, reducing hormonal response despite elevated basal cAMP levels.

In this observational study, researchers found that mini-pulse oral corticosteroids effectively reduced hair loss in alopecia areata patients who did not respond to topical therapies, though early-onset patients and those with hypothyroidism were less likely to benefit.

This review discusses the clinical features, genetics, and treatment of 21-hydroxylase deficiency, a common type of congenital adrenal hyperplasia, and reports no new research findings.

Ritlecitinib is effective and safe for treating alopecia areata, promoting significant hair regrowth.

This study found no significant difference in the severity of alopecia areata between treatments with platelet-rich plasma and triamcinolone acetonide; further high-quality trials of PRP are needed.

Wigs significantly improve the well-being of people with severe hair loss.

In this multicenter retrospective study, 61.5% of Italian patients with severe alopecia areata achieved significant hair improvement after 52 weeks of treatment with baricitinib, with no major safety issues reported, indicating long-term effectiveness in a real-world setting.

This study found that the Alopecia Areata Symptom Impact Scale (AASIS) is a better tool than the Alopecia Areata Quality of Life Index (AA-QLI) for assessing patient-reported outcomes in alopecia areata.

This study reports that combination therapy with oral steroids, anthralin, and minoxidil yielded effective cosmetic responses in 80% of patients with treatment-resistant extensive alopecia areata.

This study found that hair absorbs significant amounts of NaBr from solution, with absorption increasing linearly with solution concentration and additional effects noted with acidic or basic solutions.

This editorial proposes a new classification for alopecia areata that incorporates the SALT score and body hair involvement, aiming to improve the assessment and treatment outcomes.

This study found that patients with alopecia areata had significantly lower serum levels of 25-hydroxy vitamin D compared to control subjects.

A young man with an eating disorder had a life-threatening adrenal crisis due to an autoimmune condition, highlighting the need for better education on managing hormone treatments.

This review discusses the diagnosis and treatment of 21-hydroxylase deficiency in congenital adrenal hyperplasia and emphasizes the need for earlier detection and proper management; it reports no clinical results.

This study found that hair follicle-specific keratins can form different structural assemblies depending on ionic conditions, with hair cortex keratins requiring physiological salt conditions to form intermediate filaments.

In this study of seven randomized clinical trials, JAK inhibitors were associated with improved hair regrowth outcomes in alopecia areata patients compared to placebo, with oral administration being more effective than external application, though longer trials are needed to confirm safety and effectiveness.

This study found that trichoscopy aided in assessing treatment responses for patchy alopecia areata, with both intralesional corticosteroids and platelet-rich plasma showing effectiveness, but only PRP significantly improved patient symptom impact scores.

This study examines how the Severity of Alopecia Tool score was used to assess Alopecia Areata in patients while excluding systemic conditions that might affect vitamin D levels, but reports no new clinical results.

This study found that phototoxic psoralen and ultraviolet A therapy with topical 8-MOP was effective in treating alopecia areata resistant to other treatments, improving hair regrowth with minimal side effects.

This study found that balneophototherapy improved skin lesions in a 13-year-old with severe ichthyosis linearis circumflexa, but regular treatment is likely necessary to maintain remission.